Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TMEM109_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TMEM109_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TMEM109_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/TMEM109_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TMEM109_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007147917 | Oral cavity | OSCC | cellular response to ionizing radiation | 49/7305 | 72/18723 | 5.59e-07 | 8.13e-06 | 49 |
GO:00103326 | Oral cavity | OSCC | response to gamma radiation | 36/7305 | 56/18723 | 1.12e-04 | 8.24e-04 | 36 |
GO:00714809 | Oral cavity | OSCC | cellular response to gamma radiation | 21/7305 | 31/18723 | 1.13e-03 | 5.75e-03 | 21 |
GO:0097193110 | Oral cavity | LP | intrinsic apoptotic signaling pathway | 146/4623 | 288/18723 | 9.76e-22 | 2.78e-19 | 146 |
GO:000863019 | Oral cavity | LP | intrinsic apoptotic signaling pathway in response to DNA damage | 51/4623 | 99/18723 | 8.01e-09 | 3.20e-07 | 51 |
GO:0072331110 | Oral cavity | LP | signal transduction by p53 class mediator | 72/4623 | 163/18723 | 3.99e-08 | 1.41e-06 | 72 |
GO:0072332110 | Oral cavity | LP | intrinsic apoptotic signaling pathway by p53 class mediator | 39/4623 | 76/18723 | 5.10e-07 | 1.40e-05 | 39 |
GO:001021216 | Oral cavity | LP | response to ionizing radiation | 64/4623 | 148/18723 | 5.60e-07 | 1.51e-05 | 64 |
GO:007121417 | Oral cavity | LP | cellular response to abiotic stimulus | 121/4623 | 331/18723 | 8.45e-07 | 2.20e-05 | 121 |
GO:010400417 | Oral cavity | LP | cellular response to environmental stimulus | 121/4623 | 331/18723 | 8.45e-07 | 2.20e-05 | 121 |
GO:004277119 | Oral cavity | LP | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 25/4623 | 43/18723 | 3.00e-06 | 6.47e-05 | 25 |
GO:000931417 | Oral cavity | LP | response to radiation | 155/4623 | 456/18723 | 4.12e-06 | 8.49e-05 | 155 |
GO:007147815 | Oral cavity | LP | cellular response to radiation | 73/4623 | 186/18723 | 7.44e-06 | 1.41e-04 | 73 |
GO:007147918 | Oral cavity | LP | cellular response to ionizing radiation | 34/4623 | 72/18723 | 2.71e-05 | 4.30e-04 | 34 |
GO:001033214 | Oral cavity | LP | response to gamma radiation | 27/4623 | 56/18723 | 1.14e-04 | 1.36e-03 | 27 |
GO:007148015 | Oral cavity | LP | cellular response to gamma radiation | 17/4623 | 31/18723 | 3.09e-04 | 3.15e-03 | 17 |
GO:009719329 | Skin | cSCC | intrinsic apoptotic signaling pathway | 150/4864 | 288/18723 | 1.76e-21 | 3.34e-19 | 150 |
GO:007233129 | Skin | cSCC | signal transduction by p53 class mediator | 83/4864 | 163/18723 | 7.71e-12 | 4.00e-10 | 83 |
GO:007147824 | Skin | cSCC | cellular response to radiation | 86/4864 | 186/18723 | 1.81e-09 | 6.67e-08 | 86 |
GO:007121425 | Skin | cSCC | cellular response to abiotic stimulus | 135/4864 | 331/18723 | 2.26e-09 | 8.11e-08 | 135 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TMEM109 | insertion | Nonsense_Mutation | novel | c.531_532insCAGGAAGGAGAGACAGCCTGTTGGCCATCCCTGTAGAC | p.Ser178GlnfsTer12 | p.S178Qfs*12 | Q9BVC6 | protein_coding | | | TCGA-B6-A0I8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
TMEM109 | insertion | Frame_Shift_Ins | novel | c.98_99insGG | p.Gln34AlafsTer22 | p.Q34Afs*22 | Q9BVC6 | protein_coding | | | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
TMEM109 | insertion | Frame_Shift_Ins | novel | c.99_100insAGACAGCCACTGGAGAGTTGGGGCTGGCACAGAA | p.Gln34ArgfsTer30 | p.Q34Rfs*30 | Q9BVC6 | protein_coding | | | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
TMEM109 | insertion | Nonsense_Mutation | novel | c.136_137insGGGTCATCCTATGGCAGAAGGCAGAACCCAGCACATG | p.Lys46ArgfsTer13 | p.K46Rfs*13 | Q9BVC6 | protein_coding | | | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD |
TMEM109 | deletion | Frame_Shift_Del | novel | c.29delN | p.Gly11GlufsTer9 | p.G11Efs*9 | Q9BVC6 | protein_coding | | | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TMEM109 | SNV | Missense_Mutation | | c.690N>T | p.Gln230His | p.Q230H | Q9BVC6 | protein_coding | deleterious(0) | possibly_damaging(0.81) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TMEM109 | SNV | Missense_Mutation | novel | c.553C>T | p.Arg185Trp | p.R185W | Q9BVC6 | protein_coding | deleterious(0) | benign(0.023) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TMEM109 | SNV | Missense_Mutation | | c.298T>C | p.Ser100Pro | p.S100P | Q9BVC6 | protein_coding | tolerated(0.23) | probably_damaging(0.992) | TCGA-AY-6196-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
TMEM109 | SNV | Missense_Mutation | novel | c.50C>T | p.Ala17Val | p.A17V | Q9BVC6 | protein_coding | tolerated_low_confidence(0.7) | benign(0.001) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TMEM109 | SNV | Missense_Mutation | rs753654818 | c.310N>A | p.Ala104Thr | p.A104T | Q9BVC6 | protein_coding | deleterious(0.04) | benign(0.029) | TCGA-F4-6856-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Ancillary | leucovorin | CR |